Amgen (AMGN) also delivered strong Q2 results. EPS of $6.02 easily beat expectations, while revenue grew 9% on 13% volume growth across therapeutic areas. Sales of Repatha, a cholesterol therapy, surged 31% to $696 million. Otezla sales climbed 14% to $618 million. Even as Prolia and Enbrel faced pricing pressure, new and growing therapies more than offset the declines.